Preveceutical Medical

Preveceutical Medical EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Preveceutical Medical (PREV.CN) as of Nov 6, 2026 is -1.05 M CAD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -892,800.00 CAD — a change of 17.48% (lower).

EBITDA

-1.05 MCAD

YoY

17.48%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Preveceutical Medical is 2022 -1.05 M CAD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Preveceutical Medical was 2021 -892,800.00 CAD. It decreases by 17.48% lower compared to the previous year.

The Preveceutical Medical EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-2.70 M CAD
Jan 1, 2017
-4.47 M CAD
Jan 1, 2018
-6.89 M CAD
Jan 1, 2019
-3.33 M CAD
Jan 1, 2020
-2.07 M CAD
Jan 1, 2021
-892,800.00 CAD
Jan 1, 2022
-1.05 M CAD
The Preveceutical Medical EBITDA history
YEAREBITDAYoY
-1.05 MCAD+17.48%
-892,800.00CAD-56.77%
-2.07 MCAD-38.04%
-3.33 MCAD-51.63%
-6.89 MCAD+54.02%
-4.47 MCAD+65.45%
-2.70 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Preveceutical Medical Stock analysis

What does Preveceutical Medical do? Preveceutical Medical Inc, based in Vancouver, Canada, specializes in licensing, branding, and marketing nutraceutical and wellness products. The company, listed on 30 December 2016, focuses on developing preventive and curative therapies using organic and nature-identical products. Its pipeline includes a cannabinoid-based nose-to-brain delivery system for pain and neurological conditions, a non-addictive analgesic peptide for pain management, a BSV peptide program targeting cancer, and dual gene therapy for type 2 diabetes and obesity. The company operates through its subsidiary in Australia for research management. Preveceutical Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Preveceutical Medical stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Preveceutical Medical is -1.05 M CAD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Preveceutical Medical changed from -892,800.00 CAD to -1.05 M CAD, representing a 17.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Preveceutical Medical since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Preveceutical Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Preveceutical Medical

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Preveceutical Medical